Thermo Fisher Scientific Inc. (NYSE:TMO) Position Increased by Alliance Wealth Advisors LLC UT

Alliance Wealth Advisors LLC UT increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,897 shares of the medical research company’s stock after purchasing an additional 40 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Thermo Fisher Scientific were worth $2,069,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Russell Investments Group Ltd. increased its position in Thermo Fisher Scientific by 6.1% in the 4th quarter. Russell Investments Group Ltd. now owns 252,216 shares of the medical research company’s stock valued at $133,918,000 after acquiring an additional 14,582 shares during the period. Private Wealth Partners LLC increased its position in Thermo Fisher Scientific by 1.0% in the 4th quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock valued at $45,187,000 after acquiring an additional 815 shares during the period. Addison Advisors LLC increased its position in Thermo Fisher Scientific by 26.2% in the 4th quarter. Addison Advisors LLC now owns 231 shares of the medical research company’s stock valued at $123,000 after acquiring an additional 48 shares during the period. Gilliland Jeter Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $261,000. Finally, Golden State Equity Partners acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $346,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 5,547 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now directly owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last three months. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of Thermo Fisher Scientific stock traded up $1.87 during midday trading on Friday, hitting $573.60. The company’s stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The firm has a market capitalization of $218.95 billion, a P/E ratio of 36.79, a PEG ratio of 2.41 and a beta of 0.80. The stock has a 50-day simple moving average of $573.60 and a 200-day simple moving average of $529.90. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TMO shares. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. The Goldman Sachs Group lifted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada lifted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price on the stock. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.